This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
MB66 Film
MPT in Development
Active Ingredient:
Monoclonal Antibodies
Developer:
Mapp Biopharmaceutical, Inc.
Funding:
DAIDS
Nat. Institute Allergy & Infect. Diseases (NIAID)
NICHD
Development Stage:
Clinical – Phase 1 Trial (C1)
Delivery Route & Method:
Topical - Film - Vaginal
Mechanism of Action:
virus neutralization, mucus trapping
Product Indications:
HIV
HSV-2
Description: Plant produced anti-HIV and anti-HSV antibodies. Phase 1 clinical trial ends Q3 2018. The next generation of MB66 will include an anti-sperm human contraceptive antibody (HCA).
IMPT Secretariat
1750 Howe Avenue, Suite 550
Sacramento, CA 95825 This email address is being protected from spambots. You need JavaScript enabled to view it.
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
